Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of inhaled liposomal cyclosporine A added to standard of care for bronchiolitis obliterans syndrome after lung transplantation
2018-003205-25Phase 3Completed
- Sponsor
- Breath Therapeutics
- Start
- Nov 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Bronchiolitis Obliterans Syndrome (BOS) comparing Liposomal cyclosporine A plus standard of care with Standard of care alone (2 arms). Primary endpoint: Mean change in FEV1 from baseline. Started Nov 2018; status: completed.
02
Drugs
cyclosporine
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on 2018-003205-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003205-25.